Skip to main content
SpringerLink
Log in

Rofecoxib: a selective and effective COX-2 inhibitor

  • New Drugs and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis. Drugs. 2001 May; 61 (6); 833-65

  2. Jackson LM, Hawkey CJ. COX-2 selective nonsteroidal anti-inflammatory drugs: do they really offer any advantages? Drugs 2000 Jun; 59 (6): 1207–16

    Article  PubMed  CAS  Google Scholar 

  3. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheum 1999; 26 Suppl. 56: 18–24

    Google Scholar 

  4. Golden BD, Abramson SB. Selective cyclo-oxygenase-2 inhibitors. Rheum Dis Clin North Am 1999; 25 (2); 359–78

    Article  PubMed  CAS  Google Scholar 

  5. Cannon GW. Cyclo-oxygenase-2 selective inhibitors. Drugs Today 1999; 35 (7); 487–96

    PubMed  CAS  Google Scholar 

  6. Vane JR, Botting RM. Mechanism of action of anti-inflammatory drugs. Int J Tiss React 1998; 20 (1); 3–15

    CAS  Google Scholar 

  7. Geba GP, Weaver AL, Schnitzer TJ, et al. A clinical trial comparing rofecoxib to celecoxib and acetaminophen in the treatment of osteoarthritis (OA): early results [abstract]. Ann Rheum Dis 2000; 59 Suppl. 1: 133–4

    Google Scholar 

  8. Daniels B, Krupa D, Ehrich E, et al. Clinical response of OA patients who use acetaminophen when randomized to rofecoxib or ibuprofen [abstract]. Arthritis Rheum 1999; 42 (Suppl.): S143

    Google Scholar 

  9. Day R, Morrison B, Luza A, et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Arch Intern Med 2000; 160: 1781–7

    Article  PubMed  CAS  Google Scholar 

  10. Sagg K, van der Heijde D, Fisher C, et al. Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs. Arch Fam Med 2000; 9 (10); 1124–34

    Article  Google Scholar 

  11. van Kuijk C, Cheng X, Hottya G. the effects of rofecoxib and diclofenac on knee osteoarthritis (OA) articular cartilage: the results from one-year prospective clinical trials [abstract no. OP-082]. Ann Rheum Dis 2000; 59 Suppl. 1: 55

    Google Scholar 

  12. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Eng J Med 2000 Nov 23; 343: 1520–8

    Article  CAS  Google Scholar 

  13. Ehrich EW, Dallob A, DeLepeleire I, et al. Characterization of rofecoxib as a cyclo-oxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharm Ther 1999; 65: 336–47

    Article  CAS  Google Scholar 

  14. Malmstron K, Daniels S, Kotey P, et al. Comparison of rofecoxib and celecoxib, two cyclooxgenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and active-comparator controlled clinical trial. Clin Ther 1999; 21: 1653–63

    Article  Google Scholar 

  15. Morrison BW, Daniels SE, Kotey P, et al. Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhoea: a randomized controlled trial. Obstet Gynecol 1999; 94: 504–8

    Article  PubMed  CAS  Google Scholar 

  16. Reuben SS, Connely NR. Postoperative analgesic effects of celecoxib or rofecoxib after spinal fusion surgery. Anesth Analg 2000; 91: 1221–5

    PubMed  CAS  Google Scholar 

  17. Reicin A, Brown J, Jove M, et al. Efficacy of single-dose and multidose rofecoxib in the treatment of post-orthopedic surgery pain. Am J Ortho 2001; 30 (1); 40–8

    CAS  Google Scholar 

  18. Huang J, Taguchi A, Hsu H, et al. Preoperative oral rofecoxib does not decrease postoperative pain after radical prostatectomy. A prospective randomized, double-blind, placebo-controlled trial [abstract 941]. 2000 Annual Meeting of the American Society of Anesthesiologists, St Louis (MO)

  19. Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999 Nov 24; 282: 1929–33

    Article  PubMed  CAS  Google Scholar 

  20. Watson DJ, Harper SE, Zhao P-L, et al. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med 2000 Oct 23; 160: 2998–3003

    Article  PubMed  CAS  Google Scholar 

  21. Bombardier C, Laine L, Reicin A. Fewer gastrointestinal protective agents, procedures and hospitalizations with rofecoxib vs. naproxen in the VIGOR (VIOXX GI outcomes research) study [abstract no. 49]. Arthritis Rheum 2000; 43 Suppl: 225

    Google Scholar 

  22. Cannon GW, Caldwell JR, Holt P, et al. Rofecoxib. a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Arthritis Rheum 2000; 43: 978–987

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rofecoxib: a selective and effective COX-2 inhibitor. Drugs Ther. Perspect 18, 1–3 (2002). https://doi.org/10.2165/00042310-200218020-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200218020-00001

Keywords

Search

Navigation